Therapeutic Response Statement (Sensitivity)

This therapeutic response statement Supports the relationship that FOLR1 positive status confers therapeutic sensitivity to Mirvetuximab soravtansine in patients with High-Grade Serous Fallopian Tube Cancer.

The European Medicines Agency (EMA) has authorized mirvetuximab soravtansine for the treatment of adult patients with with folate receptor-alpha (FDalpha) positive, platinum-resistant high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment regimens.

This statement is based on a regulatory approval from the European Medicines Agency:

ELAHERE as monotherapy is indicated for the treatment of adult patients with folate receptor-alpha (FDalpha) positive, platinum-resistant high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment regimens.

Citation

AbbVie Deutschland GmbH & Co. KG. Elahere (mirvetuximab soravtansine) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/elahere-epar-product-information_en.pdf. Revised August 2025. Accessed September 8, 2025.

Contributions

Date	Contributor	Description
2025-09-08	Van Allen lab	On 2024-12-11, the EMA provided approval to Elahere (mirvetuximab soravtansine) for the treatment of adult patients with with folate receptor-alpha (FDalpha) positive, platinum-resistant high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment regimens.
2024-11-14	European Medicines Agency	Indication received approval from the European Commission.